<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37267913</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.</ArticleTitle><Pagination><StartPage>766</StartPage><EndPage>780.e9</EndPage><MedlinePgn>766-780.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2023.04.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(23)00135-2</ELocationID><Abstract><AbstractText>iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole or placebo for 24&#xa0;weeks in the double-blind period to evaluate safety, tolerability, and therapeutic effects. Adverse events were similar in both groups. During the double-blind period, muscle strength and daily activity were maintained, but a decline in the ALSFRS-R, which assesses the functional status of ALS patients, was not different from that in the placebo group. However, in the open-label extension period, the ropinirole group showed significant suppression of ALSFRS-R decline and an additional 27.9&#xa0;weeks of disease-progression-free survival. iPSC-derived motor neurons from participants showed dopamine D2 receptor expression and a potential involvement of the SREBP2-cholesterol pathway in therapeutic effects. Lipid peroxide represents a clinical surrogate marker to assess disease progression and drug efficacy. Limitations include small sample sizes and high attrition rates in the open-label extension period, requiring further validation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology and Stroke, Saitama Medical University International Medical Center, Saitama 350-1298, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dat&#xe9;</LastName><ForeName>Yugaku</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Shiho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozawa</LastName><ForeName>Fumiko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chyi</LastName><ForeName>Chai Muh</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Keio University Global Research Institute, Tokyo 108-8345, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujimori</LastName><ForeName>Koki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Tosho</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Center of Neurology, ONO Pharmaceutical Co., Ltd., Osaka 541-8564, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takao</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, National Center of Neurology and Psychiatry (NCNP), Tokyo 187-0031, Japan; Department of Neurology, Mihara Memorial Hospital, Isesaki, Gunmma 372-0006, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>Miwa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabe</LastName><ForeName>Yasuaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suematsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jinzaki</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiki</LastName><ForeName>Yuto</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Keio University Hospital Clinical and Translational Research Center, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Norihiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakahara</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Pooled Resource Open-Access ALS Clinical Trials Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: hidokano@keio.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>030PYR8953</RegistryNumber><NameOfSubstance UI="C046649">ropinirole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2023 Jun 1;30(6):748-749</RefSource><PMID Version="1">37267911</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">PRO-ACT registry data</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cholesterol synthesis</Keyword><Keyword MajorTopicYN="N">dopamine D2 receptor agonist</Keyword><Keyword MajorTopicYN="N">iPSC drug discovery</Keyword><Keyword MajorTopicYN="N">phase 1/2a trial</Keyword><Keyword MajorTopicYN="N">reverse translational research</Keyword><Keyword MajorTopicYN="N">ropinirole hydrochloride</Keyword><Keyword MajorTopicYN="N">translational research</Keyword></KeywordList><CoiStatement>Declaration of interests Outside the submitted work, K.F. reports personal fees from Sumitomo Dainippon Pharma Co., Ltd., and T.K. reports personal fees from ONO Pharmaceutical Co., Ltd. H.O. reports grants and personal fees from K Pharma, Inc. during the conduct of the study; personal fees from Sanbio Co. Ltd., outside the submitted work; In addition, H.O. has a patent on a therapeutic agent for amyotrophic lateral sclerosis and composition for treatment licensed to K Pharma, Inc. Disclosure forms provided by the authors are available with the full text of this article at Cell Stem Cell. The first draft of the manuscript was written by the first author and the co-authors provided medical writing assistance. K Pharma, Inc. reviewed the manuscript and provided feedback to authors. Authors had full editorial control of the manuscript and provided their final approval of all content. All authors vouch for the accuracy and completeness of the data, for the fidelity of the trial to the protocol, and for the complete reporting of adverse events. Confidentiality agreements were in place between authors and K Pharma, Inc. or GlaxoSmithKline K.K. (GSK).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>3</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>18</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37267913</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2023.04.017</ArticleId><ArticleId IdType="pii">S1934-5909(23)00135-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>